Loading...
NOVKAN logo

Novakand Pharma AB (publ)OM:NOVKAN Stock Report

Market Cap SEK 3.0m
Share Price
n/a
1Y-97.9%
7D-58.3%
1D-43.9%
Portfolio Value
​
View

Novakand Pharma AB (publ)

OM:NOVKAN Stock Report

Market Cap: SEK 3.0m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Novakand Pharma (NOVKAN) Stock Overview

Develops drugs for inflammatory diseases and cancer in Sweden and internationally. More details

NOVKAN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (SEK0)

Earnings have declined by 2.4% per year over past 5 years

Highly volatile share price over the past 3 months compared to the Swedish market

+ 1 more risk

NOVKAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW495,210 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
495,210 investors already sharing narratives
View all narratives

Novakand Pharma AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novakand Pharma
Historical stock prices
Current Share PriceSEK 0.025
52 Week HighSEK 2.25
52 Week LowSEK 0.022
Beta1.19
1 Month Change-74.75%
3 Month Change-82.14%
1 Year Change-97.94%
3 Year Change-99.23%
5 Year Change-99.82%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Aug 13

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 06

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 19

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 08

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 29

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 08

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 02

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 06

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 21

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Kancera...

Shareholder Returns

NOVKANSE BiotechsSE Market
7D-58.3%-3.3%-1.6%
1Y-97.9%24.2%10.4%

Return vs Industry: NOVKAN underperformed the Swedish Biotechs industry which returned 27.8% over the past year.

Return vs Market: NOVKAN underperformed the Swedish Market which returned 20.2% over the past year.

Price Volatility

Is NOVKAN's price volatile compared to industry and market?
NOVKAN volatility
NOVKAN Average Weekly Movement33.3%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market3.5%

Stable Share Price: NOVKAN's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: NOVKAN's weekly volatility has increased from 22% to 33% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20105Peter Selinnovakand.com

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025.

Novakand Pharma AB (publ) Fundamentals Summary

How do Novakand Pharma's earnings and revenue compare to its market cap?
NOVKAN fundamental statistics
Market capSEK 3.03m
Earnings (TTM)-SEK 47.23m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.1x
P/E Ratio

Is NOVKAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVKAN income statement (TTM)
RevenueSEK 0
Cost of RevenueSEK 0
Gross ProfitSEK 0
Other ExpensesSEK 47.23m
Earnings-SEK 47.23m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Apr 24, 2026

Earnings per share (EPS)-0.39
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NOVKAN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/15 06:44
End of Day Share Price 2026/04/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novakand Pharma AB (publ) is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Johan StromqvistABG Sundal Collier Sponsored
Martin WahlstromRedeye
Filip LindkvistRedeye